Targeting Key Players of Neuroendocrine Differentiation in Prostate Cancer.
lineage plasticity
neuroendocrine transdifferentiation
prostate cancer
targeted therapy
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
05 Sep 2023
05 Sep 2023
Historique:
received:
17
08
2023
revised:
02
09
2023
accepted:
03
09
2023
medline:
4
10
2023
pubmed:
28
9
2023
entrez:
28
9
2023
Statut:
epublish
Résumé
Neuroendocrine prostate cancer (NEPC) is a highly aggressive subtype of prostate cancer (PC) that commonly emerges through a transdifferentiation process from prostate adenocarcinoma and evades conventional therapies. Extensive molecular research has revealed factors that drive lineage plasticity, uncovering novel therapeutic targets to be explored. A diverse array of targeting agents is currently under evaluation in pre-clinical and clinical studies with promising results in suppressing or reversing the neuroendocrine phenotype and inhibiting tumor growth and metastasis. This new knowledge has the potential to contribute to the development of novel therapeutic approaches that may enhance the clinical management and prognosis of this lethal disease. In the present review, we discuss molecular players involved in the neuroendocrine phenotype, and we explore therapeutic strategies that are currently under investigation for NEPC.
Identifiants
pubmed: 37761978
pii: ijms241813673
doi: 10.3390/ijms241813673
pmc: PMC10531052
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Spanish Ministry of Science, Innovation and Universities
ID : PID2019-109577RA-I00/AEI/10.13039/501100011033
Organisme : Spanish Ministry of Science, Innovation and Universities (Ramón y Cajal Program)
ID : RYC-2018-023874-I
Organisme : Department of Health, Government of Navarre
ID : 026/2022
Références
J Cell Physiol. 2020 Apr;235(4):3731-3740
pubmed: 31587305
Cancer Cell Int. 2023 Jan 17;23(1):8
pubmed: 36650528
Clin Cancer Res. 2019 Feb 1;25(3):928-936
pubmed: 30037818
Endocr Relat Cancer. 2006 Mar;13(1):151-67
pubmed: 16601285
Clin Cancer Res. 2021 Sep 1;27(17):4923-4936
pubmed: 34145028
Neoplasia. 2020 Apr;22(4):192-202
pubmed: 32145689
Prostate Cancer Prostatic Dis. 2014 Sep;17(3):220-6
pubmed: 24796290
Cell Signal. 2022 Mar;91:110240
pubmed: 34986386
Nat Rev Urol. 2018 May;15(5):271-286
pubmed: 29460922
Oncotarget. 2016 Nov 15;7(46):75585-75602
pubmed: 27689328
Cell Rep. 2021 Jan 5;34(1):108585
pubmed: 33406413
Chembiochem. 2021 Jul 1;22(13):2335-2344
pubmed: 33950564
Science. 1995 Dec 1;270(5241):1491-4
pubmed: 7491495
Cancer Cell. 2010 Jul 13;18(1):23-38
pubmed: 20609350
Cell. 2018 Jul 26;174(3):758-769.e9
pubmed: 30033370
Oncologist. 2022 Nov 3;27(11):940-951
pubmed: 35983951
Proc Natl Acad Sci U S A. 2019 Oct 29;116(44):22189-22195
pubmed: 31611391
Cancer Cell. 2011 Oct 18;20(4):457-71
pubmed: 22014572
J Clin Invest. 2020 Oct 1;130(10):5338-5348
pubmed: 32634132
Proc Natl Acad Sci U S A. 2016 Nov 29;113(48):13726-13731
pubmed: 27837025
Oncotarget. 2015 Dec 29;6(42):44072-83
pubmed: 26624980
Lab Invest. 2020 Apr;100(4):570-582
pubmed: 31772313
Oncogene. 2019 Jan;38(1):17-32
pubmed: 30072740
Proc Natl Acad Sci U S A. 2020 Jan 28;117(4):2032-2042
pubmed: 31932422
Cancer Res. 2006 Nov 15;66(22):11047-54
pubmed: 17108144
Commun Biol. 2021 Jan 4;4(1):22
pubmed: 33398073
Cell Death Discov. 2019 Sep 30;5:139
pubmed: 31583122
Neoplasia. 2020 Jun;22(6):253-262
pubmed: 32403054
Eur Urol. 2017 Jan;71(1):68-78
pubmed: 27180064
J Clin Oncol. 2014 Oct 20;32(30):3391-9
pubmed: 25225437
Carcinogenesis. 2012 Jun;33(6):1169-77
pubmed: 22461520
Cell Death Dis. 2023 Jun 29;14(6):384
pubmed: 37385990
Science. 2017 Jan 6;355(6320):78-83
pubmed: 28059767
Cancer Lett. 2019 Jan;440-441:35-46
pubmed: 30312731
Eur J Cancer. 2019 Nov;121:7-18
pubmed: 31525487
Clin Cancer Res. 2019 Dec 1;25(23):6916-6924
pubmed: 31363002
Br J Cancer. 2023 Mar;128(5):918-927
pubmed: 36550208
Cancer Cell. 2016 Oct 10;30(4):563-577
pubmed: 27728805
Redox Biol. 2023 Jun;62:102686
pubmed: 36963289
Clin Cancer Res. 2019 Jan 1;25(1):43-51
pubmed: 30232224
Clin Cancer Res. 2016 Mar 15;22(6):1510-9
pubmed: 26671992
Exp Cell Res. 2014 Jan 15;320(2):188-99
pubmed: 24135225
Cancer Res. 1997 Jan 15;57(2):314-9
pubmed: 9000575
Cancer Res. 2006 May 15;66(10):4996-5002
pubmed: 16707419
Clin Cancer Res. 2018 Feb 1;24(3):708-723
pubmed: 29191973
J Immunol. 2006 Dec 15;177(12):8730-9
pubmed: 17142775
Nat Med. 2018 Dec;24(12):1887-1898
pubmed: 30478421
Nat Commun. 2018 Dec 5;9(1):5201
pubmed: 30518758
J Mol Endocrinol. 2019 Jul 1;63(1):39-49
pubmed: 31013476
Oncotarget. 2017 Dec 11;9(2):2002-2016
pubmed: 29416748
Cancer J. 2016 Sep/Oct;22(5):357-361
pubmed: 27749331
iScience. 2021 Jan 01;24(1):101970
pubmed: 33437943
Prostate. 2010 Jun 15;70(9):982-92
pubmed: 20166136
Eur Urol Oncol. 2020 Aug;3(4):540-543
pubmed: 31412002
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
J Hematol Oncol. 2020 Jul 28;13(1):104
pubmed: 32723346
Nat Rev Cancer. 2015 Dec;15(12):701-11
pubmed: 26563462
Biochim Biophys Acta Gen Subj. 2018 Mar;1862(3):589-599
pubmed: 29221985
Prostate. 2011 Oct 1;71(14):1525-37
pubmed: 21374653
Clin Cancer Res. 2015 May 15;21(10):2338-47
pubmed: 25712682
Eur J Cancer. 2017 Aug;81:228-236
pubmed: 28502694
Cancer. 2000 Jun 1;88(11):2590-7
pubmed: 10861438
Int J Mol Sci. 2022 Feb 26;23(5):
pubmed: 35269731
Histopathology. 2012 Jan;60(1):59-74
pubmed: 22212078
Anticancer Drugs. 2013 Aug;24(7):743-53
pubmed: 23652277
Nat Commun. 2017 Feb 06;8:14252
pubmed: 28165452
Oncogene. 2019 Jun;38(24):4875-4884
pubmed: 30770901
Pharmaceutics. 2023 Feb 01;15(2):
pubmed: 36839802
Cancer Res. 2018 May 15;78(10):2691-2704
pubmed: 29487201
Clin Cancer Res. 2020 Oct 15;26(20):5338-5347
pubmed: 32694156
Proc Natl Acad Sci U S A. 2018 May 1;115(18):E4179-E4188
pubmed: 29581250
Nat Rev Urol. 2021 Oct;18(10):581-596
pubmed: 34290447
PLoS One. 2021 Jan 20;16(1):e0245602
pubmed: 33471819
BJU Int. 2013 Jan;111(1):44-52
pubmed: 22928785
Prostate Cancer Prostatic Dis. 2021 Sep;24(3):623-637
pubmed: 33568748
Cancer Sci. 2023 Jun;114(6):2445-2459
pubmed: 36799474
Prostate. 2008 Feb 15;68(3):269-80
pubmed: 18163422
Cancer Res. 2009 Nov 1;69(21):8376-85
pubmed: 19843864
Cancer. 2022 Sep 1;128(17):3185-3195
pubmed: 35737639
Cell Rep. 2015 Aug 11;12(6):922-36
pubmed: 26235627
Clin Genitourin Cancer. 2019 Jun;17(3):201-208.e1
pubmed: 31056399
Prostate Cancer Prostatic Dis. 2021 Mar;24(1):268-277
pubmed: 32690869
Nat Clin Pract Urol. 2009 Feb;6(2):76-85
pubmed: 19198621
Int J Mol Sci. 2021 Mar 11;22(6):
pubmed: 33799604
Prostate. 2000 Feb 15;42(3):186-95
pubmed: 10639189
Clin Cancer Res. 2014 Jun 1;20(11):2846-50
pubmed: 24727321
Nat Commun. 2019 Jan 17;10(1):278
pubmed: 30655535
N Engl J Med. 2011 May 26;364(21):1995-2005
pubmed: 21612468
Mol Cell. 2013 Jan 10;49(1):80-93
pubmed: 23159737
Oncotarget. 2015 Jan 30;6(3):1806-20
pubmed: 25544761
N Engl J Med. 2014 Jul 31;371(5):424-33
pubmed: 24881730
Mol Cancer Res. 2020 Aug;18(8):1176-1188
pubmed: 32461304
Clin Transl Med. 2022 Feb;12(2):e695
pubmed: 35184376
JCI Insight. 2023 Aug 8;8(15):
pubmed: 37440313
Mol Cancer Ther. 2021 Sep;20(9):1680-1691
pubmed: 34158347
Endocr Relat Cancer. 2021 Jul 15;28(8):T67-T78
pubmed: 34111024
Sci Signal. 2019 Feb 05;12(567):
pubmed: 30723171
EBioMedicine. 2018 Sep;35:167-177
pubmed: 30100395
Oncologist. 2017 May;22(5):503-e43
pubmed: 28314838
Oncotarget. 2015 Apr 10;6(10):7686-700
pubmed: 25797256
Oncogene. 2016 Nov 17;35(46):5963-5976
pubmed: 26804168
Prostate Cancer. 2012;2012:593241
pubmed: 22229096
Transl Oncol. 2017 Jun;10(3):357-366
pubmed: 28342996
J Hematol Oncol. 2014 Jan 03;7:1
pubmed: 24387695
Nat Commun. 2018 Oct 4;9(1):4080
pubmed: 30287808
Nat Commun. 2020 Jan 17;11(1):338
pubmed: 31953400
Cancer Discov. 2011 Nov;1(6):487-95
pubmed: 22389870
Lancet Oncol. 2013 Dec;14(13):1307-16
pubmed: 24211163
Clin Cancer Res. 2019 Jul 1;25(13):4128-4140
pubmed: 30962287
J Pathol. 2021 Jan;253(1):106-118
pubmed: 33009820
J Biol Chem. 2007 Feb 9;282(6):3571-83
pubmed: 17148458
Clin Cancer Res. 2010 Jun 1;16(11):3028-34
pubmed: 20484019
Cancer Res. 2013 Aug 15;73(16):5288-98
pubmed: 23824741
Int J Mol Sci. 2020 Nov 05;21(21):
pubmed: 33167327
Prostate. 2019 Jan;79(1):21-30
pubmed: 30106164
Mol Oncol. 2015 Aug;9(7):1241-51
pubmed: 25817444
Front Cell Dev Biol. 2023 Jul 05;11:1206259
pubmed: 37484909
Oncotarget. 2015 Jul 10;6(19):17121-34
pubmed: 25686823
Cancer Res. 2006 Aug 15;66(16):7889-98
pubmed: 16912162
Oncogene. 2017 Jul 13;36(28):4072-4080
pubmed: 28319070
Oncotarget. 2017 Jul 19;8(49):84863-84876
pubmed: 29156689
Nat Med. 2016 Mar;22(3):298-305
pubmed: 26855148
Mol Cancer. 2021 Jan 15;20(1):15
pubmed: 33451333
J Clin Invest. 2020 Apr 1;130(4):1653-1668
pubmed: 32091413
Oncogene. 2020 Dec;39(49):7209-7223
pubmed: 33037409
Oncogene. 2009 Oct 8;28(40):3573-85
pubmed: 19633685
Curr Oncol Rep. 2021 Jan 12;23(2):15
pubmed: 33433737
Mol Cell Biol. 2001 Dec;21(24):8471-82
pubmed: 11713282
JCI Insight. 2018 Jun 21;3(12):
pubmed: 29925694
Prostate. 2014 Aug;74(11):1086-94
pubmed: 24819501
Cancers (Basel). 2022 Nov 19;14(22):
pubmed: 36428779
Front Oncol. 2021 Apr 16;11:637040
pubmed: 33937036
Nature. 2014 Jun 12;510(7504):278-82
pubmed: 24759320
Cell Death Dis. 2019 Nov 4;10(11):834
pubmed: 31685812
Cancer Res. 2021 Apr 15;81(8):2157-2170
pubmed: 33637566
Clin Cancer Res. 2018 Feb 1;24(3):696-707
pubmed: 29138344
Cell Death Dis. 2023 May 4;14(5):304
pubmed: 37142586
Sci Transl Med. 2019 Mar 20;11(484):
pubmed: 30894499
Clin Cancer Res. 2019 Nov 15;25(22):6839-6851
pubmed: 31439587
Cancer Cell. 2016 Apr 11;29(4):536-547
pubmed: 27050099
Endocr Relat Cancer. 2013 Feb 18;20(1):137-49
pubmed: 23207293
Clin Epigenetics. 2015 Apr 03;7:40
pubmed: 25859291
CA Cancer J Clin. 2023 Jan;73(1):17-48
pubmed: 36633525
Cancer Discov. 2017 Jan;7(1):54-71
pubmed: 27784708
J Clin Invest. 2018 Jan 2;128(1):341-358
pubmed: 29202480
Clin Cancer Res. 2020 Mar 1;26(5):990-999
pubmed: 31941830
Dev Biol. 2009 Apr 15;328(2):529-40
pubmed: 19389376
Cancer Cell. 2019 Mar 18;35(3):385-400.e9
pubmed: 30827887
Mol Oncol. 2021 Jul;15(7):1921-1941
pubmed: 33793068
Cell. 2013 Dec 5;155(6):1309-22
pubmed: 24315100
Sci Rep. 2017 Mar 03;7:42795
pubmed: 28256535
Oncogene. 2017 Nov 9;36(45):6213-6224
pubmed: 28692046
Proc Natl Acad Sci U S A. 2019 Oct 8;116(41):20528-20538
pubmed: 31548378
Nucleic Acids Res. 2014 Jan;42(2):999-1015
pubmed: 24163104
Cancer Med. 2018 Jul;7(7):3385-3392
pubmed: 29905005
Oncotarget. 2016 Mar 15;7(11):12372-85
pubmed: 26540632
Lancet. 2021 Jul 10;398(10295):131-142
pubmed: 34246347
Nat Commun. 2020 Nov 3;11(1):5549
pubmed: 33144576
Am Soc Clin Oncol Educ Book. 2017;37:358-369
pubmed: 28561699
Cancer Lett. 2019 May 1;449:145-162
pubmed: 30771432
Mol Cancer. 2019 Jan 18;18(1):11
pubmed: 30657058
Endocr Relat Cancer. 2011 Sep 20;18(5):R183-96
pubmed: 21778211
Clin Cancer Res. 2009 Dec 1;15(23):7421-8
pubmed: 19920114
Exp Hematol. 2011 Aug;39(8):866-79.e1
pubmed: 21689726
Cancer Lett. 2021 Oct 28;519:20-29
pubmed: 34153403
Cancers (Basel). 2021 Mar 23;13(6):
pubmed: 33807122
Prostate. 2023 Jul;83(10):936-949
pubmed: 37069746
Clin Cancer Res. 2015 Oct 15;21(20):4698-708
pubmed: 26071481
Prostate. 2008 May 15;68(7):793-801
pubmed: 18324645
Mol Cancer Res. 2016 Apr;14(4):344-53
pubmed: 26832214
Oncogene. 2003 Nov 20;22(52):8460-71
pubmed: 14627987
Clin Genitourin Cancer. 2017 Oct;15(5):e793-e800
pubmed: 28506524
Urol Oncol. 2011 Nov-Dec;29(6):682-9
pubmed: 19959380
Tzu Chi Med J. 2021 Feb 24;33(3):224-232
pubmed: 34386358
Cancer Cell. 2022 Nov 14;40(11):1306-1323.e8
pubmed: 36332622
Cancer Res. 2008 May 1;68(9):3323-33
pubmed: 18451159
Endocr Relat Cancer. 2020 Feb;27(2):R35-R50
pubmed: 31804971
Front Cell Dev Biol. 2022 Jul 22;10:955669
pubmed: 35938167